Showing results (131-140 of 379) with videos related to

Sort By:
Pageof 38
Nephrology (Carlton, Vic.)|December 23, 2014
Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis': the ACTIVE Dialysis StudyMeg J Jardine, L I Zuo, Nicholas A Gray, et al.
Kidney International Reports|May 14, 2023
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN StudyDana V Rizk, Brad H Rovin, Hong Zhang, et al.
Journal of the American Heart Association|December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS TrialTaha Sen, Jingwei Li, Brendon L Neuen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 19, 2026
Sex disparities in receiving evidence-based medications in patients with CKDRui Du, Hannah Wallace, Jeffrey T Ha, et al.
Diabetes Care|June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 26, 2020
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKDFlory T Muanda, Matthew A Weir, Lavanya Bathini, et al.
Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
The Cochrane Database of Systematic Reviews|March 2, 2013
Antiplatelet agents for chronic kidney diseaseSuetonia C Palmer, Lucia Di Micco, Mona Razavian, et al.
Kidney International Reports|January 16, 2026
Iptacopan in Patients With IgA Nephropathy From East AsiaHong Zhang, Vlado Perkovic, Jonathan Barratt, et al.
Diabetes Care|August 9, 2015
Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetesMerlin C Thomas, Mark Woodward, Bruce Neal, et al.
Pageof 38